Obesity: key endpoint results by drug
The key endpoints of Obesity trials, with each approved or late-stage drug's result from its own trial: the lead dose against placebo (or the trial's active comparator), the week, and the arm size. These are the same rows as the drug comparison, for every drug at once. To set chosen drugs side by side, with every shared endpoint, use the comparison. The drug list and pipeline are on the Obesity page.
Body weight, % change
| Drug | Result | Control | Difference | Dose · week · n | Trial |
|---|---|---|---|---|---|
| ARD-101 | -0.3% | 0.4% | −0.7 | wk 4 · n 14 | NCT05121441 Phase 2, primary |
| cagrilintide | -10.8% | -3% | −7.8 | 4.5 mg · wk 26 · n 97 | NCT03856047 Phase 2, primary |
| cagrilintide/semaglutide | -13.7%a | -3.4% | −10.3 | wk 68 | NCT05394519 Phase 3, primary |
| ecnoglutide | -13.2%a | 0.1% | −13.3 | ecnoglutide 2.4 mg · wk 40 | NCT05813795 Phase 3, primary |
| efpeglenatide | -9.8%a | -0.9% | −8.8 | wk 40 | NCT06174779 Phase 3, primary |
| eloralintide | -20.1% | -0.4% | −19.7 | 9 mg · wk 48 · n 54 | NCT06230523 Phase 2, primary |
| mazdutide | -7.3% | -0.8% | −6.5 | 3/6 mg · wk 32 · n 32 | NCT06124807 Phase 2, primary |
| metreleptin | -6.4% | -2.0% | −4.4 | 360 mcg + 1.25 mg · wk 28 · n 45 | NCT00673387 Phase 2, primary |
| naltrexone/bupropion | -7.7% | -6.5% | −1.2 | wk 12 · n 93 | NCT03374956 Phase 3, primary |
| orforglipron | -7.9% | -0.6% | −7.3 | 36 mg QD · wk 72 · n 60 | NCT05931380 Phase 3, primary |
| pemvidutide | -15.6%a | -2.2% | −13.4 | 2.4mg · wk 48 | NCT05295875 Phase 2, primary |
| phentermine/topiramate | -7.8% | -1.2% | −6.6 | wk 56 · n 488 | NCT00553787 Phase 3, primary |
| pramlintide | -5.5% | -2.0% | −3.5 | 360 mcg · wk 28 · n 51 | NCT00673387 Phase 2, primary |
| retatrutide | -17.4% | -1.6% | −15.8 | 12 mg (2 mg) · wk 24 · n 62 | NCT04881760 Phase 2, primary |
| setmelanotide | 0.4% | -0.4% | +0.8 | 2.5 mg · wk 6 · n 9 | NCT02311673 Phase 2, primary |
| survodutide | -14.9% | -2.8% | −12.1 | 4.8 mg · wk 46 · n 76 | NCT04667377 Phase 2, primary |
| zovaglutide | -13.8%a | -2.4% | −11.4 | 160mg monthly · wk 24 | NCT07020884 Phase 2, primary |
Drugs checked with no result here: 11 not posted, 10 not reported, 18 trial running.
Weight loss of 5% or more
| Drug | Result | Control | Difference | Dose · week · n | Trial |
|---|---|---|---|---|---|
| cagrilintide | 88.7% | 30.9% | +57.8 | 4.5 mg · wk 26 · n 80 | NCT03856047 Phase 2, secondary |
| eloralintide | 92.7% | 31.2% | +61.5 | 9 mg · wk 48 · n 54 | NCT06230523 Phase 2, secondary |
| mazdutide | 74.8% | 26.0% | +48.8 | 3/6 mg · wk 48 · n 32 | NCT06124807 Phase 2, secondary |
| orforglipron | 58.3% | 15% | +43.3 | 36 mg QD · wk 72 · n 60 | NCT05931380 Phase 3, primary |
| phentermine/topiramate | 62.1% | 20.8% | +41.3 | wk 56 · n 488 | NCT00553787 Phase 3, primary |
| retatrutide | 100% | 27% | +73 | 12 mg (2 mg) · wk 48 · n 62 | NCT04881760 Phase 2, secondary |
| setmelanotide | 9.1% | 5.6% | +3.5 | wk 12.857 · n 33 | NCT01749137 Phase 2, secondary |
| survodutide | 82.8% | 25.9% | +56.9 | 4.8 mg · wk 46 · n 64 | NCT04667377 Phase 2, secondary |
Drugs checked with no result here: 14 not posted, 15 not reported, 19 trial running.
Weight loss of 10% or more
| Drug | Result | Control | Difference | Dose · week · n | Trial |
|---|---|---|---|---|---|
| cagrilintide | 53.5% | 10.4% | +43.1 | 4.5 mg · wk 26 · n 80 | NCT03856047 Phase 2, secondary |
| eloralintide | 82.3% | 12.8% | +69.5 | 9 mg · wk 48 · n 54 | NCT06230523 Phase 2, secondary |
| mazdutide | 57.9% | 13.8% | +44.1 | 3/6 mg · wk 48 · n 32 | NCT06124807 Phase 2, secondary |
| orforglipron | 38.3% | 3.3% | +35 | 36 mg QD · wk 72 · n 60 | NCT05931380 Phase 3, secondary |
| retatrutide | 93% | 9% | +84 | 12 mg (2 mg) · wk 48 · n 62 | NCT04881760 Phase 2, secondary |
| survodutide | 68.8% | 11.1% | +57.7 | 4.8 mg · wk 46 · n 64 | NCT04667377 Phase 2, secondary |
Drugs checked with no result here: 15 not posted, 16 not reported, 19 trial running.
Waist circumference, change (cm)
| Drug | Result | Control | Difference | Dose · week · n | Trial |
|---|---|---|---|---|---|
| ARD-101 | -0.2 | -0.8 | +0.6 | wk 4 · n 14 | NCT05121441 Phase 2, secondary |
| bimagrumab | -9 | 0.5 | −9.4 | 10 mg/kg · wk 52 · n 36 | NCT03005288 Phase 2, secondary |
| cagrilintide | -9.5 | -3.4 | −6.1 | 4.5 mg · wk 26 · n 97 | NCT03856047 Phase 2, secondary |
| metreleptin | -4.7 | -2.5 | −2.2 | 360 mcg + 1.25 mg · wk 28 · n 45 | NCT00673387 Phase 2, secondary |
| orforglipron | -5.7 | -0.1 | −5.6 | 36 mg QD · wk 72 · n 60 | NCT05931380 Phase 3, secondary |
| phentermine/topiramate | -5.0 | 0.6 | −5.6 | wk 56 · n 54 | NCT03922945 Phase 4, secondary |
| pramlintide | -4.0 | -2.5 | −1.4 | 360 mcg · wk 28 · n 51 | NCT00673387 Phase 2, secondary |
| retatrutide | -19.6 | -2.6 | −17 | 12 mg (2 mg) · wk 48 · n 62 | NCT04881760 Phase 2, secondary |
| survodutide | -16.0 | -4.0 | −12 | 4.8 mg · wk 46 · n 75 | NCT04667377 Phase 2, secondary |
Drugs checked with no result here: 16 not posted, 11 not reported, 20 trial running.
- a From a reviewed publication or company release; CT.gov has no posted result for this endpoint.
- Each cell is from that drug's own trial. Trials differ in population, design and timepoint; this is not a head-to-head comparison.
- Rows are in drug-name order, not ranked. Difference is the lead arm minus placebo, in the endpoint's unit. 56 approved or late-stage drugs with a featured trial in Obesity were checked; results come from ClinicalTrials.gov posted results unless marked. Updated 2026-11-20. How results are chosen: methodology.